Guan Ming

Postdoctoral Fellow at the NIH (National Institutes of Health). Director of the Department of Laboratory Medicine and Director of the Central Laboratory at Huashan Hospital Affiliated to Fudan University; Deputy Director of the Research Center for Rheumatology, Immunology and Allergic Diseases at Fudan University; Deputy Director of the Institute of Molecular and Translational Medicine at Huashan Hospital. Chief Scientist of the National Key Research and Development Program; Member of the 8th National Health Standards Committee; Vice Chairman and Secretary-General of the Chinese Society of Laboratory Medicine; IFCC National Representative; Vice Chairman of the Clinical Molecular Diagnostics Branch of the Biophysical Society of China; Director of the Chinese Society of Genetics; Vice Chairman of the Tumor Gene Diagnostics Committee of the Chinese Anti-Cancer Association; Former Chairman of the Shanghai Medical Association's Laboratory Medicine Branch; Chairman of the Clinical Laboratory Medicine Professional Committee of the Shanghai Municipal Industry-Medical Integration Strategy Advisory Committee. Serves as Deputy Editor-in-Chief of Clinica Chimica Acta, Deputy Editor-in-Chief of the *Chinese Journal of Laboratory Medicine*, and Deputy Editor-in-Chief of the *International Journal of Laboratory Medicine*. Leading the construction of the cerebrospinal fluid (CSF) testing center and the development of a CSF AI-assisted diagnostic system (95% accuracy, incorporated into industry standards); spearheading the transformation of the laboratory department from a "platform department" to a "core of diagnosis and treatment," and promoting clinical translational research such as CSF liquid biopsy and the development of targeted nanoprobes for the CSF CEACAM6 gene as a biomarker for lung cancer brain metastasis. As the first author, has undertaken one National Key Research and Development Program project and eight National Natural Science Foundation of China projects; published over 120 SCI papers in journals such as Cell Discovery, ACS Nano, J Hematol Oncol, and Clinical Cancer Research; obtained 13 national invention patents, two of which have been successfully commercialized, one of which has been converted into a Class III medical device certificate; received the Third "National Renowned Doctor" Outstanding Style Award, Shanghai Leading Talent, and Shanghai Outstanding Academic Leader, among other honors.